Retargeted oncolytic viruses provoke tumor-directed T-cell responses

OncoImmunology

Volumn 4, Issue 12, 2015, Pages

  Kloos, Arnold ^a   Woller, Norman ^a   Gerardy Schahn, Rita ^a   Kühnel, Florian ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

molecular retargeting; neoepitope specific T cell responses; oncolytic virus

Indexed keywords

COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; ONCOLYTIC ADENOVIRUS; ONCOLYTIC HERPES VIRUS; ONCOLYTIC VIRUS; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; IMMUNE RESPONSE; LUNG CANCER; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; T CELL DEPLETION; T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 84944550247     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1052933     Document Type: Article

References (10)

1. R.J.Prestwich, F.Errington, R.M.Diaz, H.S.Pandha, K.J.Harrington, A.A.Melcher, R.G.Vile. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther 2009; 20:1119-32; PMID:19630549; http://dx.doi.org/10.1089/hum.2009.135
2. C.J.Breitbach, R.Arulanandam, S.N.De, S.H.Thorne, R.Patt, M.Daneshmand, A.Moon, C.Ilkow, J.Burke, T.H.Hwang, et al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res 2013; 73:1265-75; PMID:23393196; http://dx.doi.org/10.1158/0008-5472.CAN-12-2687
3. N.Woller, S.Knocke, B.Mundt, E.Gurlevik, N.Struver, A.Kloos, B.Boozari, P.Schache, M.P.Manns, N.P.Malek, et al. Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice. J Clin Invest 2011; 121:2570-82; PMID:21646722; http://dx.doi.org/10.1172/JCI45585
4. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015; PMID:26014293; [Epub ahead of print]
5. H.J.Li, M.Everts, L.Pereboeva, S.Komarova, A.Idan, D.T.Curiel, H.R.Herschman. Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic antigen bispecific adapter. Cancer Res 2007; 67:5354-61; PMID:17545616; http://dx.doi.org/10.1158/0008-5472.CAN-06-4679
6. A.Kloos, N.Woller, E.Guerlevik, C.I.Ureche, J.Niemann, N.Armbrecht, N.T.Martin, R.Geffers, M.P.Manns, R.Gerardy-Schahn, et al. PolySia-specific retargeting of oncolytic viruses triggers tumor-specific immune responses and facilitates therapy of disseminated lung cancer. Cancer Immunol Res 2015; PMID:25701327
7. V.Lennerz, M.Fatho, C.Gentilini, R.A.Frye, A.Lifke, D.Ferel, C.Wolfel, C.Huber, T.Wolfel. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A 2005; 102:16013-8; PMID:16247014; http://dx.doi.org/10.1073/pnas.0500090102
8. N.A.Rizvi, M.D.Hellmann, A.Snyder, P.Kvistborg, V.Makarov, J.J.Havel, W.Lee, J.Yuan, P.Wong, T.S.Ho, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348:124-8; PMID:25765070; http://dx.doi.org/10.1126/science.aaa1348
9. S.Kreiter, M.Vormehr, N.van de Roemer, M.Diken, M.Lower, J.Diekmann, S.Boegel, B.Schrors, F.Vascotto, J.C.Castle, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015; 520:692-6; PMID:25901682; http://dx.doi.org/10.1038/nature14426
10. S.Curreli, Z.Arany, R.Gerardy-Schahn, D.Mann, N.M.Stamatos. Polysialylated neuropilin-2 is expressed on the surface of human dendritic cells and modulates dendritic cell-T lymphocyte interactions. J Biol Chem 2007; 282:30346-56; PMID:17699524; http://dx.doi.org/10.1074/jbc.M702965200